Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TALAZOPARIB Cause Prostatic specific antigen increased? 23 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Prostatic specific antigen increased have been filed in association with TALAZOPARIB (Talzenna). This represents 1.6% of all adverse event reports for TALAZOPARIB.

23
Reports of Prostatic specific antigen increased with TALAZOPARIB
1.6%
of all TALAZOPARIB reports
2
Deaths
1
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From TALAZOPARIB?

Of the 23 reports, 2 (8.7%) resulted in death, 1 (4.3%) required hospitalization.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TALAZOPARIB. However, 23 reports have been filed with the FAERS database.

What Other Side Effects Does TALAZOPARIB Cause?

Anaemia (219) Neoplasm progression (169) Death (142) Off label use (78) Thrombocytopenia (78) Fatigue (77) Platelet count decreased (68) Haemoglobin decreased (65) Febrile neutropenia (60) Pancytopenia (60)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which TALAZOPARIB Alternatives Have Lower Prostatic specific antigen increased Risk?

TALAZOPARIB vs TALC TALAZOPARIB vs TALIGLUCERASE ALFA TALAZOPARIB vs TALIMOGENE LAHERPAREPVEC TALAZOPARIB vs TALQUETAMAB TALAZOPARIB vs TALQUETAMAB-TGVS

Related Pages

TALAZOPARIB Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased TALAZOPARIB Demographics